CN112367990A - 治疗神经病理性疼痛的方法 - Google Patents

治疗神经病理性疼痛的方法 Download PDF

Info

Publication number
CN112367990A
CN112367990A CN201980026095.5A CN201980026095A CN112367990A CN 112367990 A CN112367990 A CN 112367990A CN 201980026095 A CN201980026095 A CN 201980026095A CN 112367990 A CN112367990 A CN 112367990A
Authority
CN
China
Prior art keywords
oxy
fluorophenyl
prolinamide
phenyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201980026095.5A
Other languages
English (en)
Chinese (zh)
Inventor
Y·赵
H·奈克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CN112367990A publication Critical patent/CN112367990A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201980026095.5A 2018-04-16 2019-04-12 治疗神经病理性疼痛的方法 Withdrawn CN112367990A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658347P 2018-04-16 2018-04-16
US62/658347 2018-04-16
PCT/US2019/027158 WO2019204136A1 (en) 2018-04-16 2019-04-12 Methods of treating neuropathic pain

Publications (1)

Publication Number Publication Date
CN112367990A true CN112367990A (zh) 2021-02-12

Family

ID=68239826

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980026095.5A Withdrawn CN112367990A (zh) 2018-04-16 2019-04-12 治疗神经病理性疼痛的方法

Country Status (14)

Country Link
US (1) US20210154170A1 (https=)
EP (1) EP3781157A4 (https=)
JP (1) JP2021521227A (https=)
KR (1) KR20210002472A (https=)
CN (1) CN112367990A (https=)
AU (1) AU2019255519A1 (https=)
BR (1) BR112020021101A2 (https=)
CA (1) CA3093401A1 (https=)
EA (1) EA202092482A1 (https=)
IL (1) IL277962A (https=)
MX (1) MX2020010929A (https=)
SG (1) SG11202008681PA (https=)
TW (2) TW202245750A (https=)
WO (1) WO2019204136A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280969A1 (en) * 2005-10-10 2008-11-13 Glaxo Group Limited Novel Compounds
WO2016051194A1 (en) * 2014-10-03 2016-04-07 Convergence Pharmaceuticals Limited Erythromelalgia treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2264182A1 (en) * 1996-08-23 1998-02-26 Algos Pharmaceutical Corporation Anticonvulsant containing composition for treating neuropathic pain
GB201409851D0 (en) * 2014-06-03 2014-07-16 Convergence Pharmaceuticals Diagnostic method
JP2019537601A (ja) * 2016-11-02 2019-12-26 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 新規投薬レジメン

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080280969A1 (en) * 2005-10-10 2008-11-13 Glaxo Group Limited Novel Compounds
WO2016051194A1 (en) * 2014-10-03 2016-04-07 Convergence Pharmaceuticals Limited Erythromelalgia treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JAN M. KEPPEL HESSELINK: "Moving targets in sodium channel blocker development: the case of raxatrigine: from a central NaV1.3 blocker via a peripheral NaV1.7 blocker to a less selective sodium channel blocker" *
JOANNA M ZAKRZEWSKA等: "Novel design for a phase IIa placebo-controlled, double-blind randomized withdrawal study to evaluate the safety and efficacy of CNV1014802 in patients with trigeminal neuralgia" *
S TATE, J PALMER等: "(387) A novel proof of concept, randomized, double blind, cross-over study demonstrating the safety and efficacy of CNV1014802 in subjects with neuropathic pain from lumbosacral radiculopathy" *

Also Published As

Publication number Publication date
JP2021521227A (ja) 2021-08-26
MX2020010929A (es) 2020-11-06
TWI803619B (zh) 2023-06-01
US20210154170A1 (en) 2021-05-27
CA3093401A1 (en) 2019-10-24
AU2019255519A1 (en) 2020-10-01
IL277962A (en) 2020-11-30
SG11202008681PA (en) 2020-10-29
TW202245750A (zh) 2022-12-01
EA202092482A1 (ru) 2021-03-30
BR112020021101A2 (pt) 2021-02-23
EP3781157A1 (en) 2021-02-24
KR20210002472A (ko) 2021-01-08
WO2019204136A1 (en) 2019-10-24
EP3781157A4 (en) 2022-01-26
TW201946619A (zh) 2019-12-16

Similar Documents

Publication Publication Date Title
TWI694069B (zh) 治療精神分裂症之醫藥調配物
US20150202186A1 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
JP2024010017A (ja) 疾患処置のためのリルゾール口腔内崩壊錠の使用
WO2018221546A1 (en) Pharmaceutical composition comprising pde9 inhibitor
JP2019501162A (ja) 慢性咳の処置のためのオルブピタント
MX2014003483A (es) (rs) -2- (2-oxo-4-fenilpirrolidin-1-il)acetamida compuesto que tiene actividad moduladora con un efecto proporcionado, sustancia farmaceutica (variantes) y su aplicacion, y composicion (variantes) de la misma.
JP2025143406A (ja) 自閉症スペクトラム障害を治療するためのカルバモイルシクロヘキサン誘導体
CN112367990A (zh) 治疗神经病理性疼痛的方法
JP2023011652A (ja) 新規投薬レジメン
TW202038955A (zh) 用於治療多巴胺性cns病症之ly3154207劑量療法
US11547707B2 (en) Carbamoyl cyclohexane derivatives for treating autism spectrum disorder
HK40046223A (en) Methods of treating neuropathic pain
US20250108038A1 (en) Substituted derivatives of isoindoles and uses thereof
US20250248969A1 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
US20240269206A1 (en) Amanita muscaria extracts and compounds and their beneficial and therapeutic use
JP2019123724A (ja) 代謝型グルタミン酸作動性受容体サブタイプ２の正のアロステリック調節因子またはオルトステリックアゴニストを含む組み合わせ、およびそれらの使用
US20220235034A1 (en) Selective histamine h3 receptor antagonists for treating autism spectrum disorder
US20080033045A1 (en) Treatment of psychiatric disorders
WO2002051416A1 (fr) Medicaments ameliorant les comportements de la vie courante chez des personnes atteintes de la maladie d'alzheimer
HK1105553A (en) Multiple agent therapy for sexual dysfunction

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40046223

Country of ref document: HK

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40046223

Country of ref document: HK

WW01 Invention patent application withdrawn after publication

Application publication date: 20210212

WW01 Invention patent application withdrawn after publication